Investment strategy Life Sciences

In the area of Life Sciences, LRM focuses on companies in the early stages of development. These businesses are usually in a seed or early-stage financing round.

The investment strategy for new deals considers whether or not they complement companies already in the portfolio and existing research expertise in the broad region, especially with regard to immunology and auto-immune disorders.

LRM makes a real difference thanks to its unique combination of financial means, infrastructure and know-how.

In most cases LRM takes a minority stake in companies, with respect for the existing shareholder and management team.

The average investment horizon is situated between 5 and 10 years. The investment amounts vary between € 250.000 and € 10 million. The strong financial position of LRM allows her to participate in future investment rounds.